About the Authors

Pascal Leblanc

pascal.leblanc@univ-lyon1.fr (PL); Ina.Vorberg@dzne.de (IMV)

Affiliation Institut NeuroMyoGène INMG-PGNM, Physiopathologie et Génétique du Neurone et du Muscle, UMR5261, Inserm U1315, Université Claude Bernard UCBL-Lyon1, Faculté de Médecine Rockefeller, Lyon, France

Ina Maja Vorberg

pascal.leblanc@univ-lyon1.fr (PL); Ina.Vorberg@dzne.de (IMV)

Affiliations German Center for Neurodegenerative Diseases Bonn (DZNE), Bonn, Germany, Rheinische Friedrich-Wilhelms-Universität Bonn, Bonn, Germany

Competing Interests

I have read the journal’s policy and have the following conflicts: I. Vorberg holds pending patent applications for “HERV inhibitors for use in treating tauopathies”: “US Patent Application No. 17/640,119 based on PCT International application No. PCT/EP2020/074809, claiming priority to “European Application No. 19195304.1”.